This was the stock's second consecutive day of losses.

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

(NYSE: KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our ...

Kenvue Inc. has announced the appointment of Amit Banati as chief financial officer, effective today. He will be responsible ...

Kenvue on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a ...

Shares of Kenvue rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

The stock's rise snapped a three-day losing streak.

Discover Kenvue's Q1 2025 earnings insights—strategic growth, tariff mitigation, innovation focus, and supply chain resilience to drive performance this year.

Kenvue KVUE1.58%increase; green up pointing triangle, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial ...